[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,234
Citations 0
January 6, 2015

Cost Correction

JAMA. 2015;313(1):95. doi:10.1001/jama.2014.16454

In the article from The Medical Letter on Drugs and Therapeutics entitled “Drugs for MRSA Skin and Soft-Tissue Infections” published in the October 15, 2014, issue of JAMA (2014;312[15]:1583-1584. doi:10.1001/jama.2014.13385), the cost of tedizolid in Table 1 was reported as $2950 for 10 days’ treatment. Cubist’s tedizolid (Sivextro) received FDA approval for 6 days’ treatment of acute bacterial skin and skin structure infection, which would cost $1770. This article was corrected online.